ELVN241220C15000
- 12.46
- 0.000.00%
Enliven Therapeutics Newsroom
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating
Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
Enliven Therapeutics | 10-Q: Q3 2024 Earnings Report
Enliven Therapeutics | 8-K: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate
Express News | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 Income From Operations USD -27.068 Million
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37
Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38